Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)
CNY 3.85
(-4.7%)
CNY 3.85
(-4.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.29 Billion CNY | 33.77% |
| 2022 | 968.55 Million CNY | -24.18% |
| 2021 | 1.27 Billion CNY | 1.71% |
| 2020 | 1.25 Billion CNY | -2.48% |
| 2019 | 1.28 Billion CNY | 24.31% |
| 2018 | 1.03 Billion CNY | 847.83% |
| 2017 | -138.54 Million CNY | 66.68% |
| 2016 | -415.78 Million CNY | -98.76% |
| 2015 | -209.18 Million CNY | -332.91% |
| 2014 | 89.81 Million CNY | -69.06% |
| 2013 | 290.27 Million CNY | 1474.09% |
| 2012 | 18.44 Million CNY | 105.53% |
| 2011 | -333.76 Million CNY | 46.13% |
| 2010 | -619.53 Million CNY | -921.79% |
| 2009 | 75.38 Million CNY | -58.53% |
| 2008 | 181.8 Million CNY | -15.03% |
| 2007 | 213.95 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 1.42 Billion CNY | -4.66% |
| 2024 Q1 | 1.66 Billion CNY | 28.8% |
| 2024 Q2 | 1.53 Billion CNY | -8.06% |
| 2023 Q2 | 1.3 Billion CNY | 10.04% |
| 2023 Q3 | 1.51 Billion CNY | 16.49% |
| 2023 FY | 1.29 Billion CNY | 33.77% |
| 2023 Q4 | 1.29 Billion CNY | -14.61% |
| 2023 Q1 | 1.18 Billion CNY | 22.21% |
| 2022 Q2 | 1.33 Billion CNY | -5.19% |
| 2022 Q1 | 1.4 Billion CNY | 10.05% |
| 2022 FY | 968.55 Million CNY | -24.18% |
| 2022 Q4 | 968.55 Million CNY | -27.8% |
| 2022 Q3 | 1.34 Billion CNY | 0.65% |
| 2021 Q3 | 1.53 Billion CNY | 15.07% |
| 2021 Q2 | 1.33 Billion CNY | -18.12% |
| 2021 Q1 | 1.62 Billion CNY | 29.37% |
| 2021 Q4 | 1.27 Billion CNY | -16.56% |
| 2021 FY | 1.27 Billion CNY | 1.71% |
| 2020 Q2 | 1.63 Billion CNY | -16.05% |
| 2020 Q4 | 1.25 Billion CNY | -24.51% |
| 2020 Q1 | 1.94 Billion CNY | 50.94% |
| 2020 FY | 1.25 Billion CNY | -2.48% |
| 2020 Q3 | 1.66 Billion CNY | 1.95% |
| 2019 Q2 | 1.28 Billion CNY | 7.06% |
| 2019 FY | 1.28 Billion CNY | 24.31% |
| 2019 Q4 | 1.28 Billion CNY | -27.2% |
| 2019 Q3 | 1.76 Billion CNY | 38.18% |
| 2019 Q1 | 1.19 Billion CNY | 15.42% |
| 2018 Q4 | 1.03 Billion CNY | 145.16% |
| 2018 Q1 | 283.1 Million CNY | 304.35% |
| 2018 FY | 1.03 Billion CNY | 847.83% |
| 2018 Q2 | 279.91 Million CNY | -1.13% |
| 2018 Q3 | 422.6 Million CNY | 50.98% |
| 2017 Q1 | -133.13 Million CNY | 67.98% |
| 2017 FY | -138.54 Million CNY | 66.68% |
| 2017 Q4 | -138.54 Million CNY | -160.74% |
| 2017 Q3 | 228.08 Million CNY | 275.94% |
| 2017 Q2 | 60.67 Million CNY | 145.57% |
| 2016 FY | -415.78 Million CNY | -98.76% |
| 2016 Q4 | -415.78 Million CNY | -703.21% |
| 2016 Q3 | 68.92 Million CNY | 392.34% |
| 2016 Q1 | -23.18 Million CNY | 88.92% |
| 2016 Q2 | -23.57 Million CNY | -1.68% |
| 2015 Q3 | 90.19 Million CNY | 72.33% |
| 2015 Q1 | 191.36 Million CNY | 113.06% |
| 2015 Q4 | -209.18 Million CNY | -331.92% |
| 2015 FY | -209.18 Million CNY | -332.91% |
| 2015 Q2 | 52.34 Million CNY | -72.65% |
| 2014 FY | 89.81 Million CNY | -69.06% |
| 2014 Q3 | 161.14 Million CNY | -17.04% |
| 2014 Q1 | 279.57 Million CNY | -3.69% |
| 2014 Q4 | 89.81 Million CNY | -44.26% |
| 2014 Q2 | 194.25 Million CNY | -30.52% |
| 2013 Q4 | 290.27 Million CNY | 40.76% |
| 2013 Q3 | 206.22 Million CNY | -6.39% |
| 2013 Q2 | 220.3 Million CNY | 77.71% |
| 2013 FY | 290.27 Million CNY | 1474.09% |
| 2013 Q1 | 123.97 Million CNY | 572.27% |
| 2012 Q2 | -87.78 Million CNY | 48.96% |
| 2012 FY | 18.44 Million CNY | 105.53% |
| 2012 Q4 | 18.44 Million CNY | -80.52% |
| 2012 Q3 | 94.67 Million CNY | 207.85% |
| 2012 Q1 | -171.98 Million CNY | 48.47% |
| 2011 Q4 | -333.76 Million CNY | -2.38% |
| 2011 Q3 | -326 Million CNY | 29.33% |
| 2011 Q2 | -461.28 Million CNY | 26.57% |
| 2011 Q1 | -628.19 Million CNY | -1.4% |
| 2011 FY | -333.76 Million CNY | 46.13% |
| 2010 Q3 | -998.64 Million CNY | 23.05% |
| 2010 Q1 | 277.87 Million CNY | 268.58% |
| 2010 Q2 | -1.29 Billion CNY | -567.03% |
| 2010 FY | -619.53 Million CNY | -921.79% |
| 2010 Q4 | -619.53 Million CNY | 37.96% |
| 2009 FY | 75.38 Million CNY | -58.53% |
| 2009 Q4 | 75.38 Million CNY | 0.0% |
| 2008 FY | 181.8 Million CNY | -15.03% |
| 2007 FY | 213.95 Million CNY | 0.0% |